The major obstacle to effective cancer therapy is the development of resistance that often leads to more aggressive and harder-to-treat tumors.
What if we could develop a treatment strategy that targets the key differences between cancer and normal cells? And what if resistance to that approach could actually make cancer cells less aggressive instead of more aggressive?
We are currently dedicated to answering these questions and translating our findings into innovative therapies that can help improve the prognoses of cancer patients